Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna R C, Muggeo M
Division of Endocrinology and Metabolic Diseases, University of Verona Medical School, Verona, Italy.
Int J Obes Relat Metab Disord. 2003 Oct;27(10):1283-9. doi: 10.1038/sj.ijo.0802381.
The present study aimed at evaluating the prevalence of the Metabolic Syndrome and at identifying its additional clinical features.
Within a prospective population-based survey examining 888 subjects aged 40-79 y, subjects were identified fulfilling the WHO and the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria for diagnosing the Metabolic Syndrome. In these subjects and in the rest of the sample (controls), several metabolic and nonmetabolic biochemical parameters were compared.
The prevalence of the Metabolic Syndrome by WHO criteria was 34.1% (95% CI 31.0-37.2) and by NCEP-ATPIII criteria 17.8% (15.5-20.3). The prevalence was significantly higher in older subjects and in those less physically active. Subjects with the Metabolic Syndrome either by WHO or by NCEP-ATPIII criteria showed higher levels of oxidized low-density lipoprotein, apolipoprotein B, urate, leptin, fibrinogen, leukocytes, erythrocyte sedimentation rate, GOT, gamma-GT and soluble endothelial adhesion molecules (E-selectin, vascular adhesion molecule-1 and intercellular adhesion molecule-1) and lower apolipoprotein A concentrations. Insulin resistance, as assessed by the Homeostasis Model Assessment, increased with the increase in the number of traits composing the syndrome found within the single individual. Subjects with insulin resistance had more pronounced abnormalities in several parameters, including the additional features of the syndrome (eg fibrinogen and soluble adhesion molecules).
The Metabolic Syndrome occurs very frequently in the general population aged 40-79 y, and is associated with several additional metabolic and nonmetabolic abnormalities that likely contribute to an increased cardiovascular risk. Insulin resistance seems to play a major role in classic and additional abnormalities featuring the Metabolic Syndrome.
本研究旨在评估代谢综合征的患病率,并确定其额外的临床特征。
在一项基于人群的前瞻性调查中,对888名年龄在40 - 79岁的受试者进行检查,确定符合世界卫生组织(WHO)和美国国家胆固醇教育计划成人治疗小组第三次报告(NCEP - ATPIII)代谢综合征诊断标准的受试者。对这些受试者以及其余样本(对照组)的多项代谢和非代谢生化参数进行比较。
根据WHO标准,代谢综合征的患病率为34.1%(95%可信区间31.0 - 37.2),根据NCEP - ATPIII标准为17.8%(15.5 - 20.3)。患病率在老年受试者和体力活动较少的受试者中显著更高。无论是根据WHO还是NCEP - ATPIII标准诊断为代谢综合征的受试者,其氧化型低密度脂蛋白、载脂蛋白B、尿酸、瘦素、纤维蛋白原、白细胞、红细胞沉降率、谷草转氨酶、γ - 谷氨酰转肽酶和可溶性内皮黏附分子(E - 选择素、血管细胞黏附分子 - 1和细胞间黏附分子 - 1)水平较高,而载脂蛋白A浓度较低。通过稳态模型评估法评估的胰岛素抵抗,随着个体中构成该综合征的特征数量增加而增加。有胰岛素抵抗的受试者在多个参数上有更明显的异常,包括该综合征的额外特征(如纤维蛋白原和可溶性黏附分子)。
代谢综合征在40 - 79岁的普通人群中非常常见,并且与一些额外的代谢和非代谢异常相关,这些异常可能导致心血管风险增加。胰岛素抵抗似乎在代谢综合征的典型和额外异常中起主要作用。